The association of betaine, homocysteine and related metabolites with cognitive function in Dutch elderly people. by Eussen, S. et al.
PDF hosted at the Radboud Repository of the Radboud University
Nijmegen
 
 
 
 
The following full text is a publisher's version.
 
 
For additional information about this publication click this link.
http://hdl.handle.net/2066/53652
 
 
 
Please be advised that this information was generated on 2017-12-06 and may be subject to
change.
The association of betaine, homocysteine and related metabolites
with cognitive function in Dutch elderly people
Simone J. P. M. Eussen1*, Per M. Ueland2, Robert Clarke3, Henk J. Blom4, Willibrord H. L. Hoefnagels5,
Wija A. van Staveren1 and Lisette C. P. G. M. de Groot1
1Division of Human Nutrition, Wageningen University, P.O. Box 8129 6700 EV Wageningen, The Netherlands
2Section for Pharmacology, Institute of Medicine, University of Bergen and Haukeland University Hospital, Armauer Hanssen Hus
(Building), 5021 Bergen, Norway
3Clinical Trial Service Unit and Epidemiological Studies Unit, University of Oxford, Oxford OX3 7LF, UK
4Department of Clinical Chemistry, VU University Medical Center, PO Box 7057 1007 MB Amsterdam, The Netherlands
5Department of Geriatrics, University Medical Center Nijmegen, PO Box 9101 6500 HB Nijmegen, The Netherlands
(Received 14 August 2006 – Revised 29 March 2007 – Accepted 3 April 2007)
The importance of the one-carbon metabolites, choline and homocysteine, to brain function is well known. However, the associations between the
one-carbon metabolites choline, betaine, methionine and dimethylglycine with cognition in elderly are unclear. We therefore examined the associ-
ations of these metabolites with cognition in a double-blind, placebo-controlled trial. Individuals (n 195) were randomized to receive daily oral
capsules with either 1000mg cobalamin (vitamin B12), or 1000mg cobalamin plus 400 mg folic acid, or placebo for 24 weeks. Concentrations of
homocysteine, methionine, choline, betaine and dimethylglycine were assessed before and after 12 and 24 weeks of treatment. Cognitive function,
including domains of attention, construction, sensomotor speed, memory and executive function, was assessed before and after 24 weeks of treat-
ment. At baseline, elevated plasma homocysteine was associated with lower performance of attention, construction, sensomotor speed and execu-
tive function. In addition, betaine was positively associated with better performance of construction, sensomotor speed and executive function,
whereas elevated concentrations of methionine were positively associated with sensomotor speed. Daily combined supplementation with cobala-
min plus folic acid decreased total homocysteine concentrations by 36%, and increased betaine concentrations by 38%. Participants with the lar-
gest increases in betaine concentrations showed a borderline significant (P¼0·07) higher memory performance compared to those without it.
Although this trial observed associations of homocysteine and betaine with cognitive domains prior to supplementation, decreased concentrations
of homocysteine were not related to improved cognitive performance. There was a tendency of participants with the largest increases in betaine
concentrations to show the greatest improvement in memory function.
Elderly: Homocysteine: Choline: Betaine: Dimethylglycine: Cognition
Elucidation of the risk factors for cognitive decline is required
to prevent and possibly reverse age-related cognitive impair-
ment in elderly people. In this respect, the one-carbon metab-
olism is of interest because plasma concentrations of
homocysteine and related B-vitamins have been associated
with cognitive impairment1–6. Moreover, choline plays an
important role in normal brain development, in particular for
memory and learning7.
The metabolites of the one-carbon metabolism are closely
interrelated8,9. Homocysteine is located at a critical metabolic
branch point with ramification to methyl- and sulphur group
metabolism (Fig. 1). Homocysteine is formed from the essen-
tial amino acid methionine. Methionine is activated by its con-
version to S-adenosylmethionine, and S-adenosylmethionine is
required for methylation of many acceptor substrates, such
as DNA, RNA, lipids, proteins, phosphatidylethanolamine,
creatine, myelin basic protein and neurotransmitters10.
Methylation of, for example, phosphatidylethanolamine to form
phosphatidylcholine, is important to maintain myelin sheaths
of nerve tissue and thereby for central nervous system struc-
ture and function7. Homocysteine is remethylated to methion-
ine by the cobalamin (vitamin B12)-dependent enzyme,
methionine synthase, which uses 5-methyltetrahydrofolate as
a methyl donor. Deficiencies of folate and cobalamin impair
this conversion and result in increased homocysteine concen-
trations11. In a few tissues, predominantly the liver and kid-
neys, homocysteine remethylation is also catalysed by the
enzyme betaine-homocysteine methyltransferase. Methionine
and dimethylglycine (DMG) are the products of this reaction.
The methyl donor, betaine, is formed from choline, which also
is a precursor for the neurotransmitter acetylcholine12. Concei-
vably, impaired one-carbon metabolism may be associated
with cognitive impairment by affecting neurotransmitter
metabolism and central nervous system function.
*Corresponding author: Dr Simone Eussen, fax þ47 31 317 482 782, email Simone.Eussen@farm.uib.no
Abbreviations: DMG, dimethylglycine; MMSE, Mini-Mental State Examination; tHcy, total homocysteine.
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Following the epidemiological associations found be-
tween homocysteine, cobalamin and folate with cognitive per-
formance1–6, recent intervention trials investigated the
efficacy of homocysteine lowering with B-vitamin supplemen-
tation on cognitive function in elderly people13–15. How-
ever, the associations of plasma concentrations of choline,
betaine, DMG and methionine with cognitive performance
have not been explored yet. A recently conducted effi-
cacy trial, investigating the efficacy of oral cobalamin with
or without folic acid supplementation on cognitive function14,
provided such an opportunity. In addition, we assessed
whether supplementation with cobalamin and folic acid
altered plasma concentrations of choline, betaine and DMG,
and consequently, whether alterations in these metabolites
were associated with improvements in cognitive function.
Subjects and methods
Participants
Elderly men and women aged 70 years or older were screened
for participation in a randomized double-blind placebo-con-
trolled trial that studied the efficacy of oral cobalamin sup-
plementation on cognitive performance14. Individuals were
included when they had mild cobalamin deficiency, defined
as serum cobalamin concentrations between 100 and
300 pmol/l in combination with plasma methylmalonic acid
concentrations $0·32mmol/l and serum creatinine concen-
tration #120mmol/l to exclude severe impairment of renal
function16. Other exclusion criteria were history of cobalamin
deficiency, use of cobalamin (.50mg/d) or folic acid
(.200mg/d) supplementation or injections, surgery or dis-
eases of the stomach or small intestine, anaemia, life-threatening
diseases, severe hearing or visual problems, and severe cogni-
tive impairment, which was defined by a score ,19 points on
the Mini-Mental State Examination (MMSE). An additional
sample of individuals with adequate cobalamin status and no
severe cognitive impairment (n 40) was enrolled for cross-sec-
tional data analysis. Figure 2 presents the recruitment pro-
cedure, study design and flow of participants. The Medical
Ethical Committee of Wageningen University approved the
study protocol. Daily boards and client councils gave their
consent for those individuals living in an institution, and writ-
ten informed consent from all participants was obtained before
the start of the study.
Study design of the intervention trial
Individuals who were included in the intervention trial started
with a 2-week placebo run-in period prior to randomization.
Within this period, individuals were excluded from further
participation if compliance (intake of capsules) was ,90%,
or if they scored ,19 points on the MMSE. Eligible partici-
pants were randomized to receive 24 weeks of treatment in
a parallel group design with daily oral doses of 1000mg coba-
lamin, a combination of 1000mg cobalamin and 400mg folic
acid, or a placebo capsule. Randomization was stratified
according to methylmalonic acid concentration at the screen-
ing visit (below and above 0·45mmol/l), age (below and
above 80 years), sex and MMSE (below and above 24 points).
Blood collection and biochemical analyses
A blood sample was collected at the screening and baseline
visit and after 12 and 24 weeks of supplementation. A blood
Fig. 1. B-vitamins (B6 and B12), homocysteine (Hcy), choline, betaine and the one-carbon metabolism. The conversion from Hcy to methionine (Met) can be cata-
lysed by methionine synthase (MS) and betaine-homocysteine methyltransferase (BHMT). The conversion via MS requires cobalamin and 5-methyltetrahydrofo-
late (THF) as a methyl donor and couples folate metabolism to the choline-betaine pathway. Choline is provided by food or can be formed de novo via sequential
S-adenosylmethionine (SAM)-dependent methylation of phosphatidylethanolamine (PE) to form phosphatidylcholine (PC) by phosphatidylethanolamine N-methyl-
transferase (PEMT). Choline is a precursor for the neurotransmitter acetylcholine or it is oxidized to betaine. Betaine donates its methyl group directly to homocys-
teine for the conversion into methionine, and results in dimethylglycine (DMG) in the BHMT reaction. CBS, cystathionine-b-synthase; CH3THF,
methyltetrahydrofolate; cysta, cystathionine; MTR, methionine synthase; SAH, S-adenosylhomocysteine.
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sample for measurement of methionine, total homocysteine
(tHcy), choline, betaine and DMG was collected into a
10ml Vacutainerw tube containing EDTA. This blood
sample was placed in ice-water and centrifuged at 2600 rpm
for 10min at a temperature of 48C within 30min of collection.
All plasma samples were stored at 2808C prior to laboratory
analyses. Plasma concentrations were determined by a method
based on methylchloroformate derivatization and GC–MS
(methionine and tHcy)17 and a modification of a method
based on liquid chromatography tandem MS (choline, betaine
and DMG)18. Analytical CV of the assays for methionine,
tHcy, choline, betaine and DMG were ,3·4, ,2·2, ,10,
,10 and ,10%, respectively17,18.
Assessment of cognitive function
Six trained and registered neuropsychologists performed cog-
nitive testing of the participants during a 1·5–2 h session
during the run-in period and at week 24 of intervention. The
cognitive test battery consisted of tests that have been
shown sensitive to the effects of B-vitamin treatment and
ageing in previous studies2,19. Individuals were screened by
the MMSE, and those with an MMSE score ,19 points
(maximum 30 points) were excluded because of severe cogni-
tive impairment20. Table 1 lists the order of assessment and
description of the tests, including its corresponding cognitive
domain and neuropsychological focus. All these single tests
were clustered into domains of attention, construction, senso-
motor speed, memory and executive function, as indicated in
the statistical methods. Three out of five domains were
assessed by at least two tests that measured different aspects
and/or degrees of complexities, which has been proposed as
the preferred method for cognitive testing21. The advantages
of clustered scores are (1) the reduction of measurement
errors by possible floor and ceiling effects from difficult and
easy tests, respectively; (2) to be able to account for missing
data; (3) data reduction and thereby reducing chance findings;
and finally (4) a better sensitivity to measure cognitive
changes21,22.
Statistical methods
The average concentrations of the biochemical parameters at
the screening and randomization visits were calculated for
each individual, and defined as ‘baseline’ concentrations.
Differences in concentrations of blood parameters at baseline
and follow-up were assessed with a two-factor repeated
measures ANOVA (two measurements £ three treatment
groups) that included the time £ treatment interaction. Tukey
post hoc tests were used to assess differences between the
intervention groups.
Data on cognitive function were presented as the neuropsy-
chological domains of attention, construction, sensomotor
speed, memory and executive function. The domains of atten-
tion and construction were assessed by a single cognitive test,
while the other domains were assessed by multiple tests.
All crude test scores were transformed to z-scores by: z-
score ¼ ((individual result – mean result of study population
at baseline)/standard deviation of study population at base-
line). The multiple tests for the domains of sensomotor
speed, memory and executive function were clustered to
provide compound z-scores to reduce the effects of chance
findings and to simplify interpretation of the cognitive data:
Attention ¼ ZDigit Span Forward; Construction ¼ ZRey,copy; Sen-
somotor speed ¼ (2ZMotor Planning (2) þ 2 ZFinger Tapping þ 2
Z
Trail Making (part A)
)/3; Memory ¼ (Z15 Word Learning, immediate þ Z15
Word Learning, delayed þ Z15 Word Learning, recognition þ ZRey,
immediate þ ZRey, delayed þ ZDigitSpan Backward)/6; Executive
function ¼ (2ZMotor Planning (3) þ 2 ZTrail Making (partC/
partA) þ 2 ZStroop (part3/part2) þ ZSimilarities (WAIS) þ ZRaven þ
Z
Word Fluency (Animals)
þ ZWord Fluency (Letter))/7.
Tests that were clustered for each cognitive domain were
highly correlated (P values ranged from ,0·0001 to 0·04 for
all tests). Some participants were unable to complete all
tests because of performance difficulties, e.g. tiredness. Com-
pound z-scores were calculated when data for at least two,
four and five tests for the domains of sensomotor speed,
memory and executive function, respectively, were available.
The compound z-scores served as ‘internal’ z-scores from
Fig. 2. Recruitment procedure, study design and flow of Dutch elderly participants.
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Table 1. Description of neuropsychological test battery with corresponding domain and neuropsychological focus
Task and reference* Domain Neuropsychological focus Description Baseline score
MMSE34 All Global cognitive function Screening tool. Exclusion from further participation
if score , 19 points at first visit
27 ^ 3 points (max. 30)
Finger Tapping,
computerized35
Sensomotoric speed Simple sensomotor speed Press a single button as often as possible within 30 s 442 ^ 247 ms to press a button
Motor Planning_2,
computerized35
Sensomotoric speed Simple visuomotor reaction Press a lit button out of three buttons as quickly as
possible
665 ^ 344 ms to press a button
Motor Planning_3,
computerized35
Executive function Complex visuomotor
reaction
Inhibit automatic reaction in pressing a button
immediately adjacent to a lit button as
quickly as possible
1015 ^ 503 ms to press a button
Figure of Rey – copy36 Construction Visuoconstruction Copy the complex figure of Rey from an example 28 ^ 8 points (max. 36)
Figure of Rey –
immediate recall36
Memory Visual immediate memory Draw the complex figure of Rey without the example
immediately after the copy
10 ^ 7 points (max. 36)
15 Word Learning –
immediate recall37
Memory Verbal immediate memory Read fifteen words five times and recall words in
between reading
30 ^ 11 correct words recalled
Trail Making A38 Sensomotoric speed Visuomotor speed Connect randomly placed numbers with a line as
fast as possible
77 ^ 43 s to complete task
Trail Making B38 Executive function Concept shifting Connect randomly placed numbers and letters
alternated with a line as fast as possible
207 ^ 141 s to complete task
Digit Span Forward39 Attention Attention Repeat a string of digits in original order 7·5 ^ 1·7 (max. 16)
Digit Span Backward39 Memory Working memory Repeat a string of digits in reverse order 4·9 ^ 1·7 (max. 14)
Raven40 Executive function Visual reasoning Choose a design that fits into a matrix 15·4 ^ 3·9 (max. 24)
Stroop41,42 Executive function Interference Name colour of the ink while inhibiting the automatic
response of reading rather than the word (part 3).
Part 1: reading names of colours red, green, yellow,
blue; part 2: naming coloured blocks red, green,
yellow, blue
Part 1: 0·61 ^ 0·21 false
Part 2: 1·37 ^ 0·68 false
Part 3: 5·97 ^ 3·45 false
answers
Figure of Rey –
delayed recall36
Memory Visual delayed memory Draw the complex figure of Rey without the
example 30 min after seeing the copy
9·7 ^ 6·9 (max. 36)
15 Word Learning –
delayed recall37
Memory Verbal delayed memory Recall the words of the fifteen word learning test 4·8 ^ 3·5 (max. 15)
15 Word Learning –
recognition37
Memory Consolidation Recognize the original fifteen words, of thirty words read 25·8 ^ 3·9 (max. 30)
Similarities (WAIS)43 Executive function Verbal reasoning Mention similarities between five pairs of nouns 4·9 ^ 2·9 (max. 12)
Verbal Fluency, letter44 Executive function Word generation List as many nouns beginning with letter P
(0 weeks) or G (24 weeks) as possible in 2 min
15·4 ^ 6·9 nouns listed
Verbal Fluency, animal44 Executive function Word generation List as many animals as possible in 1 min 17·5 ^ 5·7 animals listed
GDS45 Emotional status Depression Self-rating scale for depression 2·9 ^ 2·9 (max. 15)
GDS, Geriatric Depression Scale; MMSE, Mini-Mental State Examination.
* Ordered by assessment.
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which z-scores at baseline and 24 weeks by study treatment
were derived.
Baseline information of the present study population with
mild cobalamin deficiency combined with an additional
group of elderly with adequate cobalamin status enabled us
to explore associations between the one-carbon metabolites
and cognitive performance by means of partial correlation
coefficients which were corrected for age and education.
Per protocol analyses were performed, including only the
162 participants (84%) who completed the trial. Changes in
cognitive performance associated with alterations of metab-
olite concentration were calculated by subtracting z-scores at
the end of the intervention study by the z-scores at baseline.
The potential effects of changes in metabolites on cognitive
function within each domain within and across tertile cat-
egories in biochemical changes were studied by a two-factor
repeated measures analyses (two measurements £ three tertile
categories) for each cognitive domain that included the time £
tertile category interaction term. These analyses were per-
formed with mixed models (SAS PROC MIXED procedure23),
an extension from the linear regression model that includes
random effects. Possible inter-investigator bias of the six
neuropsychologists was entered as random effects. Statistical
analyses were conducted using SAS statistical software ver-
sion 9.1 (SAS Institute Inc., Cary, NC, USA).
Results
Characteristics of participants
Cross-sectional analyses have been performed for 202 elderly
with mild cobalamin deficiency and forty elderly with ade-
quate cobalamin status. The mean age of these participants
was 81 (SD 6) years, 74% of the participants were females,
and 40% of the participants lived in a care facility home.
The mean score on the MMSE was 27 (SD 3) points which
indicates that most of the population had intact cognitive func-
tion or only mild impairment.
The demographic, lifestyle and co-morbidity characteristics
of participants are presented in Table 2. Although there were
some differences with respect to lifestyle, medical history and
mental status between those with mild cobalamin deficiency
and those with adequate cobalamin status, there were no
differences between those with mild cobalamin deficiency
and the total population used for cross-sectional analyses
(Table 2). Of the individuals with mild cobalamin deficiency
who started with the run-in period (n 202), seven showed
second thoughts, resulting in 195 participants who underwent
random assignment. Two of these 195 participants dropped
out during the run-in period, which left data for 193 partici-
pants who started supplementation (Fig. 2).
Table 2. Characteristics of older participants
Mild cobalamin
deficiency (n 202;
intervention study)*
Adequate
cobalamin
status (n 40)
Total population
cross sectional
analyses (n 242)
Demography
Age, mean (SD) years† 82 ^ 5 79 ^ 6 81 ^ 6
Sex, male, n (%)‡ 50 (25) 13 (33) 63 (26)
Living, institutionalized, n (%)‡ 90 (45) 6 (15) 96 (40)
Education level, n (%)
Low‡ 80 (40) 4 (10) 84 (35)
Middle 92 (45) 17 (43) 109 (45)
High‡ 30 (15) 19 (47) 49 (20)
Lifestyle n (%)
Ex-Smokers‡ 63 (31) 3 (8) 66 (27)
Smokers 18 (9) 2 (5) 20 (8)
Social drinking, n (%)‡ 85 (42) 8 (20) 93 (38)
Vegetarian, n (%)‡ 10 (5) 0 (0) 10 (4)
Multivitamin use, n (%)‡ 39 (19) 3 (8) 42 (17)
Medical history
Myocardial infarction, n (%)‡ 30 (15) (0) 30 (12)
Stroke, n (%)‡ 10 (5) (0) 10 (4)
Transient ischaemic attack, n (%)‡ 3 (19) 1 (3) 40 (17)
Angina pectoris, n (%)‡ 34 (17) 4 (10) 38 (16)
Diabetes mellitus, n (%) 19 (9) 3 (8) 22 (9)
Hypertension, n (%)‡ 56 (27) 4 (10) 60 (25)
H2 antagonist/proton pump inhibitors, n (%)‡ 49 (24) 1 (3) 50 (21)
Neurological symptoms
MMSE, mean (SD) points‡ 26·6 ^ 3·2 28·9 ^ 1·5 27·0 ^ 3·1
19–24 points (cognitive impairment), n (%)‡ 37 (18) 1 (3) 38 (16)
GDS, mean (SD) points 2·9 ^ 2·6 3·2 ^ 4·1 3·0 ^ 2·9
. 5 points (depression), n (%)‡ 42 (21) 5 (13) 47 (19)
GDS, Geriatric Depression Scale; MMSE, Mini-Mental State Examination.
* No significant differences between the three treatment groups were observed (one-way ANOVA for continuous variables and x2
analyses for categorical variables): P.0·05.
† Values are means and standard deviations.
Values were significantly different from those of the adequate cobalamin group (unpaired t-test for continuous variables and x2 analyses
for categorical variables): ‡P,0·05.
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Blood indices and cognitive function before supplementation
Mean concentrations for methionine (25·1mmol/l), choline
(8·0mmol/l), betaine (32·2mmol/l) and DMG (3·7mmol/l) in
the total screened population (n 896) did not differ from
those concentrations observed in the segment of participants
involved in the intervention trial (n 193; P.0·05 for all indi-
ces (unpaired t-test)). Partial correlation coefficients between
the blood indices of the total screened population (n 896),
which were corrected for age and sex, are presented in
Table 3. Consistent with the inclusion criteria of mild cobala-
min deficiency, participants of the intervention trial had lower
cobalamin concentrations and higher tHcy concentrations
compared to the total screened population (both P,0·0001).
Partial correlation coefficients, which were corrected for
age and education, revealed inverse associations of tHcy
concentrations with compound scores for the domains of
attention, construction, sensomotor speed and executive func-
tion. Methionine concentrations were positively associated
with the domain of sensomotor speed, whereas betaine con-
centrations were positively associated with the domains of
construction, sensomotor speed and executive function
(Table 3). Further adjustment of our analysis for emotional
status and other co- morbidity factors did not affect these
associations (data not shown). Moreover, the observed associ-
ations did not essentially differ between mildly cobalamin-
deficient participants and those cobalamin-replete subjects
(data not shown).
Changes in blood indices during intervention
Table 4 presents the concentrations of vitamins and the one-
carbon metabolites at baseline and at 24 weeks of supplemen-
tation. Concentrations of all metabolites in the placebo group
remained stable throughout the study period. The time £
treatment interaction term was significant for cobalamin,
tHcy, erythrocyte folate (P,0·0001 for these indices) and
betaine (P¼0·030), which indicates differences in effects
between the intervention groups. The effects of treatment
did not differ between the intervention groups (no significant
interaction terms) for methionine, choline and DMG. Never-
theless, concentrations of methionine and choline increased
significantly by 11 and 23%, respectively, after combined
supplementation.
Cognitive performance and changes in blood indices
No differences in cognitive performance between intervention
groups were observed at baseline. Since some participants
were unable to complete all tests, data of 141, 158 and 151
participants were included for analyses on the domains of
sensomotor speed, memory and executive function, respect-
ively. There were no significant effects of increases in
erythrocyte folate and cobalamin concentrations on cognitive
performance, and this had been described elsewhere14.
Table 5 presents mean changes in cognitive scores according
to changes in tHcy, methionine, choline, betaine and DMG,
which are categorized into tertiles. In the domain of
memory, the time £ tertile category interaction term was
only significant for DMG (P¼0·04), and borderline significant
for betaine (P¼0·07), which indicates differences in memory
improvement between the tertiles. Participants with the largest
increases in betaine concentrations (third tertile category;
change in betaine concentrations .6·88mmol/l) showed the
highest increase in memory performance compared to those
in the first and second tertiles. For DMG, participants in the
second and third tertiles had a better memory performance
compared to those in the first tertile. With respect to the
other cognitive domains, no effects within and between tertiles
were observed. Further adjustment of our analysis for
emotional status and other co-morbidity factors did not
affect these associations (data not shown). With respect to
emotional status, there were no significant changes in Geriatric
Depression Scores between the intervention groups after 24
weeks of supplementation (P¼0·32).
Table 3. Partial Spearman rank correlation coefficients between one-carbon metabolites and
vitamins with one-carbon metabolites, and between one-carbon metabolites with compound cognitive
domains in a Dutch elderly population (n 242) prior to supplementation
One-carbon metabolites
n Choline Betaine DMG tHcy Methionine
Metabolites
Choline 896 0·42** 0·40** 0·14** 0·24**
Betaine 896 0·35** 20·23** 0·21**
DMG 896 0·24** 0·21**
tHcy 896 20·04
Cobalamin 896 0·03 0·09* 0·04 20·27** 0·12
Erythrocyte folate 896 0·09* 0·24** 20·05 20·41** 0·13**
Cognition
Attention 238 20·02 0·04 20·07 20·12† 0·01
Construction 236 0·06 0·19†† 0·03 20·18†† 0·01
Sensomotor speed 222 20·07 0·14†† 20·03 20·26†† 0·16
Memory 237 0·00 0·01 20·02 20·07 0·02
Executive function 233 0·00 0·13†† 0·01 20·14†† 0·10
DMG, dimethylglycine; tHcy, total homocysteine.
Partial correlation coefficients corrected for age and sex: *P,0·05; **P,0·0001.
Partial correlation coefficients corrected for age and education: †P,0·10; †† , 0·05.
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Table 4. Concentrations of vitamins and one-carbon metabolites at baseline and 24 weeks after
supplementation with cobalamin (vitamin B12), cobalamin þ folic acid or placebo in a Dutch elderly
population
Cobalamin Cobalamin þ folic acid Placebo
n Mean SD n Mean SD n Mean SD
Homocysteine (mmol/l)*
Baseline† 52 15·6 6·6 50 14·5 4·4 55 15·8 5·6
24 weeks‡ 52 12·8§ 4·9 51 8·9§ 2·4 54 16·1 6·8
Methionine (mmol/l)k
Baseline 55 24·2{ 4·0 50 24·5{ 3·9 55 26·6 5·1
24 weeks† 54 25·5 6·9 51 26·2§ 5·5 54 26·2 5·5
Choline (mmol/l)k
Baseline 52 8·5 1·9 50 7·8{ 1·6 55 8·8 1·9
24 weeks† 52 9·0 2·3 51 9·6§ 2·4 54 9·0 2·7
Betaine (mmol/l)*
Baseline† 52 32·9 10·1 50 30·4 6·4 55 33·4 9·5
24 weeks 52 34·6 12·0 51 40·9§** 0·5 54 36·2 12·8
DMG (mmol/l)k
Baseline 52 4·2 1·6 50 3·5** 0·7 55 3·8 1·1
24 weeks 52 4·3 2·2 51 3·5** 0··9 54 3·9 1·1
* Treatment effects (changes from baseline within groups) significantly different between the three treatment
groups, as indicated by a significant time £ treatment interaction (ANOVA): P,0·05.
† No significant differences between the three treatment groups (ANOVA with Tukey post hoc tests): P.0·05.
‡ Significant differences between the three treatment groups (ANOVA with Tukey post hoc tests): P,0·05.
Mean values were significantly different from those of the baseline (ANOVA repeated-measures analysis with
LSMEANS): §P,0·05.
kTreatment effects (changes from baseline within groups) not significantly different between the three treatment
groups, as indicated by a non-significant time £ treatment interaction (ANOVA): P.0·05.
Mean values were significantly different from those of the placebo (ANOVA with Tukey post hoc tests): {P,0·05.
Mean values were significantly different from those of the cobalamin group (ANOVA with Tukey post hoc tests):
**P,0·05.
Table 5. Mean cognitive changes in z-scores by tertiles in changes of one-carbon metabolites due to cobalamin with or without folic acid supplementation
in a Dutch elderly population (n 195)*
tHcy Methionine Choline Betaine DMG
Mean 95 % CI Mean 95 % CI Mean 95 % CI Mean 95 % CI Mean 95 % CI
Attention
Tertile 1 0·03 20·18, 0·25 0·05 20·20, 0·29 0·01 20·19, 0·21 0·10 20·14, 0·34 20·06 20·27, 0·14
Tertile 2 0·02 20·26, 0·31 0·11 20·14, 0·35 0·24 20·03, 0·50 20·04 20·27, 0·20 0·23 20·04, 0·49
Tertile 3 0·10 20·13, 0·34 0·00 20·24, 0·18 20·08 20·35, 0·18 0·08 20·17, 0·33 0·01 20·24, 0·27
P trend 0·8991 0·7358 0·6289 0·7091 0·4811
Construction
Tertile 1 0·06 20·11, 0·24 0·13 20·07, 0·32 0·15 20·05, 0·36 0·21 0·01, 0·42 0·03 20·16, 0·22
Tertile 2 0·13 20·02, 0·27 0·12 20·06, 0·30 0·14 20·02, 0·31 0·12 20·07, 0·31 0·24 0·05, 0·42
Tertile 3 0·21 20·002, 0·44 0·16 20·03, 0·35 0·10 20·10, 0·29 0·05 20·11, 0·21 0·15 20·04, 0·34
P trend 0·8494 0·1738 0·5745 0·0669 0·0602
Sensomotor speed
Tertile 1 0·07 20·08, 0·22 0·01 20·14, 0·17 0·03 20·11, 0·16 0·05 20·10, 0·20 0·05 20·10, 0·20
Tertile 2 0·00 20·12, 0·12 0·02 20·11, 0·15 0·02 20·12, 0·16 0·01 20·12, 0·14 0·03 20·08, 0·15
Tertile 3 20·03 20·16, 0·12 0·01 20·12, 0·15 0·00 20·14, 0·15 20·02 0·15, 0·12 20·03 20·18, 0·11
P trend 0·9569 0·4994 0·7232 0·0857 0·4233
Memory
Tertile 1 0·25 20·02, 0·52 0·28 0·20, 0·40 0·29 0·17, 0·40 0·25a,b 0·13, 0·38 0·17a 0·08, 0·26
Tertile 2 0·23 0·00, 0·45 0·28 0·16, 0·40 0·30 0·21, 0·39 0·20a 0·09, 0·31 0·35b 0·23, 0·48
Tertile 3 0·35 0·07, 0·63 0·28 0·14, 0·42 0·26 0·13, 0·39 0·38b 0·29, 0·50 0·33b 0·21, 0·45
P trend 0·1287 0·2767 0·3253 0·1000 0·4522
Executive function
Tertile 1 0·03 20·10, 0·16 0·04 20·08, 0·15 0·05 20·06, 0·15 0·08 20·02, 0·19 0·01 20·11, 0·13
Tertile 2 0·03 20·06, 0·12 0·08 0·00, 0·17 0·05 20·07, 0·17 20·01 20·14, 0·11 0·14 0·05, 0·23
Tertile 3 0·12 0·03, 0·22 0·06 20·06, 0·18 0·08 20·01, 0·17 0·10 0·00, 0·20 0·03 20·08, 0·15
P trend 0·2966 0·9950 0·2676 0·2518 0·9345
DMG, dimethylglycine; tHcy, total homocysteine.
a,b Mean changes in z-scores with unlike superscript letters were significantly different (P,0·05).
* At baseline, mean compound z-scores were essentially 0 (SD 1), as a result of standardizing and combining crude cognitive scores into standardized compound z-scores.
Analyses are adjusted for age, education and neuropsychologists. The cut-off points for tertile categories in changes of tHcy were 23·95 and 20·7mmol/l; for methionine
they were 21·32 and 2·88mmol/l; for choline they were 20·17 and 1·48mmol/l; for betaine they were 21·43 and 6·88mmol/l; and for DMG they were 20·33 and
0·41mmol/l. P values indicate tests for trend across median changes in concentrations for each tertile. Analyses are corrected for age, education and neuropsychologist.
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Discussion
The present study showed that elevated plasma tHcy was
associated with lower performance of attention, construction,
sensomotor speed and executive function. In addition, betaine
was positively associated with better performance of construc-
tion, sensomotor speed and executive function, whereas elev-
ated concentrations of methionine were positively associated
with sensomotor speed prior to supplementation. Daily oral
supplementation of 1000mg cobalamin with 400mg folic
acid for a period of 24 weeks decreased tHcy concentrations
and increased betaine concentrations. There was a tendency
for participants with the largest increases in betaine concen-
trations to show the greatest improvement in memory function.
To our knowledge, the current study is the first one that
explores associations of cognitive functionwith choline, betaine
and DMG in an elderly population. Previous animal24,25 and
human8,9,26 studies indicate a strong interrelationship between
the betaine-homocysteine methyltransferase and methionine
synthase pathways. This is reflected in lower hepatic choline
concentrations during folate deficiency25,26 and vice versa24,
inverse relations between betaine and homocysteine during
folate deficiency8, and increased betaine concentrations after
folic acid supplementation9. The latter findings9 are in line
with results of the present trial.
Conceivably, diseases associated with high plasma tHcy
concentrations may not only be linked to low concentrations
of cobalamin and folate, but also with low concentrations of
betaine and choline. So far, only one non-placebo-controlled
pilot study in eight patients with Alzheimer’s disease27 have
investigated the effect of oral betaine supplementation, and
their results were negative. In contrast, the present trial
showed that participants with the largest increases in betaine
concentrations (third tertile category; change in betaine con-
centrations .6·88mmol/l) showed the highest increase in
memory performance compared to those in the first and
second tertile categories. Given the fact that the changes in
betaine and homocysteine concentrations were most pro-
nounced in the group supplemented with cobalamin plus
folate, and were related to the increase in erythrocyte folate
concentrations (Table 3), it is possible that folate supplemen-
tation accounted for the observed cognitive changes. However,
of the recently reported trials13–15, only the FACIT trial has
observed a beneficial effect of folate supplementation on
memory function15. The inconclusive results among the
reported trials could possibly be explained by variations in
study durations, sample sizes, characteristics of study popu-
lation and assessment of cognitive function.
The apparent effect of the increase in betaine concentrations
on improved memory function may also reflect greater
availability of choline metabolites for synthesis of the
neurotransmitter acetylcholine and several phospholipids,
such as phosphatidylcholine and sphingomyelin28. Choline
metabolism is closely related to several aspects of the central
nervous system function and structure. An adequate supply of
choline appears to be essential for fetal cholinergic neuronal
development, in particular for brain regions involved in learn-
ing and memory processes28. Choline is a precursor of brain
sphingomyelin, which is a component of white matter
myelin7. It has been proposed that changes in white matter
sphingomyelin or phospholipid content precede clinical
deterioration in demyelinating diseases such as multiple scler-
osis29. There is some evidence that supplementation with cyti-
dinediphospho-choline could protect against and prevent
memory impairment in ageing rats30,31, and has beneficial
effects on memory and behaviour in elderly people with cog-
nitive problems32. The present study describes the association
of plasma choline with cognitive status, and the absence of
associations prior to supplementation is inconsistent with the
hypothesis that choline status is related to cognitive impair-
ment. The lack of associations between plasma choline and
cognitive function in the present study may reflect the possi-
bility that plasma free choline represents only a minor fraction
of the total choline pool7, and may be a poor marker of choline
status and metabolism in the brain, which has also been pre-
viously suggested33.
For DMG, participants in the second and third tertile had a
better memory performance compared to those in the first ter-
tile. This observation may reflect changes in cognition during
altered betaine metabolism because there is a positive relation
between the two metabolites at low but not high DMG con-
centrations8. However, the DMG–memory association could
be a chance finding. This possibility is strengthened by the
observation that DMG did not change during the intervention.
In summary, the present trial is the first to explore associ-
ations of cognitive function with choline, betaine and DMG.
We observed associations of homocysteine and betaine with
cognitive domains prior to B-vitamin supplementation. Fur-
thermore, there was a tendency that participants with the lar-
gest increases in betaine concentrations due to combined
supplementation with cobalamin plus folic acid showed the
greatest improvement in memory performance.
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